Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
22.72
+0.89 (4.08%)
At close: Feb 20, 2026, 4:00 PM EST
22.28
-0.44 (-1.94%)
After-hours: Feb 20, 2026, 7:20 PM EST
Ultragenyx Pharmaceutical Revenue
In the year 2025, Ultragenyx Pharmaceutical had annual revenue of $673.00M with 20.18% growth. Ultragenyx Pharmaceutical had revenue of $207.28M in the quarter ending December 31, 2025, with 25.89% growth.
Revenue (ttm)
$673.00M
Revenue Growth
+20.18%
P/S Ratio
3.26
Revenue / Employee
$520,093
Employees
1,294
Market Cap
2.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 673.00M | 113.00M | 20.18% |
| Dec 31, 2024 | 560.00M | 126.00M | 29.03% |
| Dec 31, 2023 | 434.00M | 70.67M | 19.45% |
| Dec 31, 2022 | 363.33M | 11.92M | 3.39% |
| Dec 31, 2021 | 351.41M | 80.38M | 29.66% |
| Dec 31, 2020 | 271.03M | 167.32M | 161.32% |
| Dec 31, 2019 | 103.71M | 52.22M | 101.41% |
| Dec 31, 2018 | 51.50M | 48.88M | 1,871.48% |
| Dec 31, 2017 | 2.61M | 2.48M | 1,863.91% |
| Dec 31, 2016 | 133.00K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.41B |
| Harmony Biosciences Holdings | 825.94M |
| Aurinia Pharmaceuticals | 265.81M |
| Vericel | 258.72M |
| Nektar Therapeutics | 62.60M |
| Nuvation Bio | 26.75M |
| Dianthus Therapeutics | 3.08M |
RARE News
- 8 hours ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 days ago - Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE - GlobeNewsWire
- 7 days ago - Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Why Is Ultragenyx Stock Sinking Friday? - Benzinga
- 8 days ago - Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update - GlobeNewsWire
- 11 days ago - UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical - Newsfile Corp
- 11 days ago - RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit - PRNewsWire
- 17 days ago - Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA) - GlobeNewsWire